- Conditions
- Lymphoblastic Lymphoma
- Interventions
- Prednisone, Vincristine, Daunorubicin, PEG-asparaginase, Erwinia asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Hydrocortisone, Etoposide
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 38
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Azacitidine, Decitabine, Cytarabine, Daunorubicin, Etoposide, ITMHA, Idarubicin, Fludarabine, Mitoxantrone, Erwinia asparaginase, Sorafenib, G-CSF, Dexrazoxane, Stem Cell Transplant, Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn
- Drug · Combination Product · Biological
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 10
- States / cities
- Madera, California • Orange, California • Palo Alto, California + 7 more
- Conditions
- T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
- Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Other · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 1,895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 191
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
- Interventions
- Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 7
- States / cities
- Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
- Conditions
- Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated With Down Syndrome, Myeloproliferative Neoplasm
- Interventions
- Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine, Daunorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Thioguanine
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 91 Days to 3 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 169
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 131 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Topotecan, dexamethasone, vincristine, E. coli Asparaginase, PEG-L-asparaginase, erwinia asparaginase, fludarabine, methotrexate, mercaptopurine, idarubicin, etoposide, cytarbine, teniposide, chemotherapy, intrathecal chemotherapy, steroid therapy
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative, Aged 60 Years or Older
- Interventions
- Erwinia Chrysanthemi asparaginase
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 60 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
- Interventions
- ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Cyclophosphamide, 6-thioguanine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 2 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2022
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- ITMHA, Dexamethasone, Mitoxantrone, Pegaspargase, Asparaginase Erwinia Chrysanthemi, Bortezomib, Vorinostat, Cyclophosphamide, Mercaptopurine, Methotrexate, Leucovorin Calcium, Cytarabine, Etoposide, Vincristine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 365 Days
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2031
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 6 more
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Lumbar Puncture, Mercaptopurine, Methotrexate, Positron Emission Tomography, Rituximab, Vincristine Sulfate
- Drug · Procedure · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Duarte, California • Irvine, California + 5 more
- Conditions
- Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
- Interventions
- Bortezomib, Vorinostat, Mitoxantrone, Cytarabine, Methotrexate, Hydrocortisone, Peg-L-Asparaginase, Erwinia L-Asparaginase, Dexamethasone, Mercaptopurine, Doxorubicin
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 365 Days
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 98 more
- Conditions
- Lymphoblastic Leukemia, Acute
- Interventions
- Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplantation
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 501 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2014
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee • Fort Worth, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic
- Interventions
- Etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase, chemotherapy, intrathecal chemotherapy, steroid therapy, Hematopoietic Stem Cell Transplant, Natural Killer (NK) Cell Transplant
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Leukemia
- Interventions
- Erwinase
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
- Interventions
- Dexamethasone, Panobinostat, Liposomal vincristine, Mitoxantrone, Peg-asparaginase, Bortezomib, Intrathecal Triples, High-dose methotrexate, 6-Mercaptopurine, High-dose cytarabine, Nelarabine, Cyclophosphamide, Etoposide, Clofarabine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
- Interventions
- Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Drug · Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 365 Days to 31 Years
- Enrollment
- 6,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 201
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- asparaginase Erwinia chrysanthemi
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange County, California • Palo Alto, California + 15 more
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Diagnostic Imaging Testing, Inotuzumab Ozogamicin, Leucovorin Calcium, Lumbar Puncture, Methotrexate, Pegaspargase, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 127 more
- Conditions
- Leukemia
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, prednisone, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 9 Years
- Enrollment
- 1,970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 31
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 24 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Erwinase
- Drug
- Lead sponsor
- Ashkan Emadi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland